- Home
- NNY vs ELDN Comparison
NNY vs ELDN Comparison
Compare NNY & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- ELDN
- Stock Information
- Founded
- NNY 1987
- ELDN 2004
- Country
- NNY United States
- ELDN United States
- Employees
- NNY N/A
- ELDN N/A
- Industry
- NNY Investment Managers
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- NNY Finance
- ELDN Health Care
- Exchange
- NNY Nasdaq
- ELDN Nasdaq
- Market Cap
- NNY 159.8M
- ELDN 164.1M
- IPO Year
- NNY N/A
- ELDN N/A
- Fundamental
- Price
- NNY $8.38
- ELDN $1.49
- Analyst Decision
- NNY
- ELDN Strong Buy
- Analyst Count
- NNY 0
- ELDN 2
- Target Price
- NNY N/A
- ELDN $12.50
- AVG Volume (30 Days)
- NNY 50.9K
- ELDN 3.8M
- Earning Date
- NNY 01-01-0001
- ELDN 11-14-2025
- Dividend Yield
- NNY 4.04%
- ELDN N/A
- EPS Growth
- NNY N/A
- ELDN N/A
- EPS
- NNY N/A
- ELDN N/A
- Revenue
- NNY N/A
- ELDN N/A
- Revenue This Year
- NNY N/A
- ELDN N/A
- Revenue Next Year
- NNY N/A
- ELDN N/A
- P/E Ratio
- NNY N/A
- ELDN N/A
- Revenue Growth
- NNY N/A
- ELDN N/A
- 52 Week Low
- NNY $7.58
- ELDN $1.43
- 52 Week High
- NNY $8.87
- ELDN $5.08
- Technical
- Relative Strength Index (RSI)
- NNY 50.12
- ELDN 26.44
- Support Level
- NNY $8.40
- ELDN $1.60
- Resistance Level
- NNY $8.58
- ELDN $2.40
- Average True Range (ATR)
- NNY 0.13
- ELDN 0.32
- MACD
- NNY -0.01
- ELDN -0.24
- Stochastic Oscillator
- NNY 28.29
- ELDN 1.82
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.